A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain

Primary objectives: To compare alvimopan with placebo for long-term safety and tolerability
Primary endpoints: Incidence of reported clinical adverse events, including serious and non-serious adverse events as well as treatment-limiting adverse events